Oxford Endovascular is a medical device company that develops advanced neurovascular technologies for patients with brain aneurysms. It offers OxiFlow, a novel flow-diverter that diverts blood flow away from intracranial aneurysms at risk of rupture, places more accurately and safely reducing the risk of complications, and conforms better to blood vessels making more patients treatable. The company focuses on brain hemorrhage prevention to address unmet clinical needs.
|Employees (est.) (Nov 2021)||8||(+15%)|
Oxford Endovascular total Funding
Oxford Endovascular latest funding size
Time since last funding
|8 months ago|
Oxford Endovascular investors
|European Commission, EIT Health, Perivoli Innovations, Parkwalk Advisors, Oxford Investment Consultants, the University of Oxford, Vulpes Investment Management, Additio Investment Group, Oxford Sciences Innovation PLC, Smart Grant Program, Perivoli|
When was Oxford Endovascular founded?
Oxford Endovascular was founded in 2015.
Who are Oxford Endovascular key executives?
Oxford Endovascular's key executives are Chas Taylor, James Byrne and Mike Karim.
How many employees does Oxford Endovascular have?
Oxford Endovascular has 8 employees.
Who are Oxford Endovascular competitors?
Competitors of Oxford Endovascular include Sanyou Medical, ADORA and Filterlex Medical.
Where are Oxford Endovascular offices?
Oxford Endovascular has an office in Oxford.
How many offices does Oxford Endovascular have?
Oxford Endovascular has 1 office.
Receive alerts for 300+ data fields across thousands of companies